abstract: BACKGROUND: There have been no reports concerning the correlation between @entity1 and @entity5 . METHODS AND RESULTS: From January 2000 to December 2007, 201 @entity0 with @entity1 were hospitalized at our institution. We could perform coronary arteriography and @entity4 provocation tests in 37 (22 @entity0 , 67  11 years) out of 201 @entity0 with @entity1 before discharge. @entity2 was observed in 13 @entity0 (35%). After controlling @entity1 and 24h cessation of vasoactive drugs, pharmacological @entity4 provocation tests were performed. Positive @entity4 was defined as >90%. @entity5 was observed in 12 @entity0 (32%) and multiple @entity4 was recognized in 10 (83%) out of 12 @entity0 . Though ejection fraction on admission was not different between the two groups (42  18% vs. 43  11%, ns), left ventricular end-diastolic and end-systolic dimension after medical therapy over 1 year was significantly smaller in @entity0 with positive @entity4 than that in @entity0 with negative @entity4 . There was no difference concerning medications except the administration of @entity3 and @entity6 between two groups. CONCLUSIONS: @entity5 , especially multiple @entity4 , may cause transient @entity1 in a small part of unknown origin @entity1 in Japan.

title: @entity1 : multiple XXXX may cause transient @entity1 ?

answer: @entity4


abstract: BACKGROUND: @entity1 is associated with higher morbidity and mortality in @entity0 with @entity2 ( @entity2 ), but its implications for heath care costs are not well described. METHODS AND RESULTS: We analyzed data on 1056 @entity0 with symptomatic @entity2 seen at Duke University between 2002 and 2006. Health care costs were obtained from the hospital cost accounting data system. Adjustments for censoring and covariate imbalance were performed using inverse probability weighted estimators and propensity scores. The prevalence of @entity1 was 32%. Unadjusted mortality at 3 years was 50.3% in anemic versus 26.5% in non-anemic @entity0 . The adjusted costs per year alive were  22,926 for @entity0 with @entity1 and  17,189 for those without (P=.04). For those with ejection fraction <or=40% adjusted costs per year alive were  32,914 for anemic versus  18,423 for non-anemic @entity0 (P=.01). CONCLUSIONS: @entity1 in @entity2 @entity0 was independently associated with greater total costs after accounting for differences in survival, but appeared to be confined primarily to @entity0 with low ejection fraction. These results provide a framework for understanding the economic implications of therapies for @entity1 in @entity2 , and suggest that targeting @entity0 with impaired systolic function has the potential to most favorably affect costs.

title: Relationship between @entity1 and health care costs in XXXX .

answer: @entity2


abstract: BACKGROUND: @entity1 is associated with higher morbidity and mortality in @entity0 with @entity2 ( @entity2 ), but its implications for heath care costs are not well described. METHODS AND RESULTS: We analyzed data on 1056 @entity0 with symptomatic @entity2 seen at Duke University between 2002 and 2006. Health care costs were obtained from the hospital cost accounting data system. Adjustments for censoring and covariate imbalance were performed using inverse probability weighted estimators and propensity scores. The prevalence of @entity1 was 32%. Unadjusted mortality at 3 years was 50.3% in anemic versus 26.5% in non-anemic @entity0 . The adjusted costs per year alive were  22,926 for @entity0 with @entity1 and  17,189 for those without (P=.04). For those with ejection fraction <or=40% adjusted costs per year alive were  32,914 for anemic versus  18,423 for non-anemic @entity0 (P=.01). CONCLUSIONS: @entity1 in @entity2 @entity0 was independently associated with greater total costs after accounting for differences in survival, but appeared to be confined primarily to @entity0 with low ejection fraction. These results provide a framework for understanding the economic implications of therapies for @entity1 in @entity2 , and suggest that targeting @entity0 with impaired systolic function has the potential to most favorably affect costs.

title: Relationship between XXXX and health care costs in @entity2 .

answer: @entity1


abstract: OBJECTIVE: Unawareness of impairment ( @entity4 ) is a phenomenon associated with right hemisphere lesions. Unawareness of emotion has rarely been studied. METHODS: @entity0 (N = 50) with @entity2 were administered the Toronto, Ontario, Canada, Alexithymia Scale to assess impairment in identifying feelings (F1), describing feelings (F2), and externally oriented thinking (F3). After eight weeks of treatment with @entity5 or @entity3 , @entity0 were reassessed. RESULTS: Alexithymia was significantly associated with right hemisphere lesions. @entity0 with alexithymia had a significant improvement in identifying and describing feelings, but not in externally oriented thinking. In addition, cognitive functions improved after antidepressant treatment in @entity0 without alexithymia with left lesions only. On the contrary, functional activities of daily living and depressive symptoms improved both in @entity0 with alexithymia and those without alexithymia. CONCLUSIONS: The unawareness of emotions is a common impairment after right hemisphere @entity1 . This disorder may be significantly improved by antidepressant treatment.

title: Response of emotional unawareness after XXXX to antidepressant treatment.

answer: @entity1


abstract: Automutilistic behaviour is frequently correlated with @entity2 and should be differentiated from suicidal behaviour during acute episodes of @entity3 . The aim of the study was to investigate psychotherapeutically and psychodynamically significant personality traits and affect regulation. The dimensions "relationship", "conflict" and "structure" were examined by means of Operationalized Psychodynamic Diagnostics. SAMPLE: 20 female @entity0 with @entity1 and automutilistic behaviour and 20 age-matched female subjects with a similar educational background, suffering from @entity1 without automutilistic behaviour. RESULTS The female @entity0 with @entity1 and automutilistic behaviour could be differentiated from the control group in all categories in the OPD dimension "structure". They showed an "isolated" and "disclosed" self-image. This negative self-perception corresponded with a negative countertransference. There were no differences between the @entity0 with automutilistic behaviour and the control group regarding the OPD dimension "conflict". Low and moderate levels of integration were prominently correlated with the autonomy-dependence conflict. CONCLUSION The results underline the significance of aspects of personality structure in automutilistic behaviour seen in female @entity0 with @entity1 . Operationalized Psychodynamic Diagnostics can reveal therapeutically relevant personality dimensions for empirical research.

title: [Automutilistic behaviour in female @entity0 with XXXX : investigation of personality structure and affect regulation by means of Operationalized Psychodynamic Diagnostics (OPD)].

answer: @entity3


abstract: Automutilistic behaviour is frequently correlated with @entity2 and should be differentiated from suicidal behaviour during acute episodes of @entity3 . The aim of the study was to investigate psychotherapeutically and psychodynamically significant personality traits and affect regulation. The dimensions "relationship", "conflict" and "structure" were examined by means of Operationalized Psychodynamic Diagnostics. SAMPLE: 20 female @entity0 with @entity1 and automutilistic behaviour and 20 age-matched female subjects with a similar educational background, suffering from @entity1 without automutilistic behaviour. RESULTS The female @entity0 with @entity1 and automutilistic behaviour could be differentiated from the control group in all categories in the OPD dimension "structure". They showed an "isolated" and "disclosed" self-image. This negative self-perception corresponded with a negative countertransference. There were no differences between the @entity0 with automutilistic behaviour and the control group regarding the OPD dimension "conflict". Low and moderate levels of integration were prominently correlated with the autonomy-dependence conflict. CONCLUSION The results underline the significance of aspects of personality structure in automutilistic behaviour seen in female @entity0 with @entity1 . Operationalized Psychodynamic Diagnostics can reveal therapeutically relevant personality dimensions for empirical research.

title: [Automutilistic behaviour in female XXXX with @entity3 : investigation of personality structure and affect regulation by means of Operationalized Psychodynamic Diagnostics (OPD)].

answer: @entity0


abstract: BACKGROUND: @entity3 is the most common progressive @entity2 . In recent years, numerous progresses in the discovery of novel @entity3 molecular biomarkers in brain as well as in biological fluids have been made. Among them, those involving lipid metabolism are emerging as potential candidates. In particular, an accumulation of neutral lipids was recently found by us in skin fibroblasts from @entity3 @entity0 . Therefore, with the aim to assess whether peripheral alterations in @entity1 homeostasis might be relevant in @entity3 development and progression, in the present study we analyzed lipid metabolism in plasma and peripheral blood mononuclear cells from @entity3 @entity0 and from their first-degree relatives. METHODS: Blood samples were obtained from 93 @entity0 with probable @entity3 and from 91 of their first-degree relatives. As controls we utilized 57, cognitively normal, over-65 year-old volunteers and 113 blood donors aged 21-66 years, respectively. Data are reported as mean +/- standard error. Statistical calculations were performed using the statistical analysis software Origin 8.0 version. Data analysis was done using the Student t-test and the Pearson test. RESULTS: Data reported here show high neutral lipid levels and increased @entity4 protein in about 85% of peripheral blood mononuclear cells freshly isolated (ex vivo) from @entity0 with probable sporadic @entity3 compared to about 7% of cognitively normal age-matched controls. A significant reduction in high density lipoprotein- @entity1 levels in plasma from @entity3 was also observed. Additionally, correlation analyses reveal a negative correlation between high density lipoprotein- @entity1 and cognitive capacity, as determined by Mini Mental State Examination, as well as between high density lipoprotein- @entity1 and neutral lipid accumulation. We observed great variability in the neutral lipid-peripheral blood mononuclear cells data and in plasma lipid analysis of the subjects enrolled as @entity3 -first-degree relatives. However, about 30% of them tend to display a peripheral metabolic @entity1 pattern similar to that exhibited by @entity3 @entity0 . CONCLUSION: We suggest that neutral lipid-peripheral blood mononuclear cells and plasma high density lipoprotein- @entity1 determinations might be of interest to outline a distinctive metabolic profile applying to both @entity3 @entity0 and asymptomatic subjects at higher risk of disease.

title: Accumulation of neutral lipids in peripheral blood mononuclear cells as a distinctive trait of Alzheimer XXXX and asymptomatic subjects at risk of disease.

answer: @entity0


abstract: BACKGROUND: @entity9 and @entity8 are associated with an @entity6 due to apoptosis. Whether cardiomyocyte apoptosis plays a causal role in the pathogenesis of @entity8 remains enigmatic. The apoptosis repressor with caspase recruitment domain ( @entity11 ) is a recently discovered antiapoptotic factor with a highly specific expression pattern in striated muscle and neurons. @entity11 is a master regulator of @entity3 signaling because it is the only known factor that specifically inhibits both the intrinsic and extrinsic apoptotic death pathway. In this study we attempted to elucidate the physiological role of @entity11 and to understand pathophysiological consequences resulting from its deletion. METHODS AND RESULTS: We generated @entity11 @entity1 , which developed normally to adulthood and had no abnormality in cardiac morphology and function under resting conditions. On biomechanical stress induced by aortic banding, @entity11 @entity1 developed accelerated @entity4 compared with littermate controls, which was characterized by reduced contractile function, @entity5 , and @entity4 . Likewise, @entity2 /reperfusion injury of @entity11 @entity1 resulted in markedly increased @entity7 sizes. Although in both instances a significant increase in apoptotic cardiomyocytes could be observed in @entity11 @entity1 , neither in vitro nor in vivo studies revealed any effect of @entity11 on classic @entity10 cardiomyocyte growth responses. The pathophysiological relevance of downregulated @entity11 levels was underscored by specimens from failing @entity0 hearts showing markedly reduced @entity11 protein levels. CONCLUSIONS: Our study identifies a tissue-specific antiapoptotic factor that is downregulated in @entity0 failing myocardium and that is required for cardioprotection in pressure overload and @entity2 .

title: Apoptosis repressor with caspase recruitment domain is required for cardioprotection in response to biomechanical and XXXX stress.

answer: @entity2


abstract: BACKGROUND: Recently, the concept of the @entity2 ( @entity2 ) has emerged in an effort to group and study as a whole several cardiovascular risk factors. The @entity2 requires the presence of 3 or more of the following parameters: high blood pressure (>/= 130/85), waist circumference >102 cm in @entity0 and >88 cm in @entity0 , HDL<50 mg/dL in @entity0 and <40 mg/dL in women, serum @entity5 >150 mg/dL and fasting blood @entity4 >/= 110 mg/dL. OBJECTIVES: To investigate the prevalence of the @entity2 and the specific @entity0 characteristics in a cohort of hemodialysis @entity0 . MATERIALS AND METHODS: 102 stable @entity0 on maintenance hemodialysis (63 male/39 female with a mean time on dialysis of 57.19 +/- 47.16 months) were studied for 12 months. RESULTS: The prevalence of the @entity2 is high (56.25%) during the first year on dialysis and gradually declines (44.8% from 2-5 years and 29.7% for >5 years). In total 41/102 @entity0 had @entity2 (40.19%); 28/41 were @entity0 (68.29%) and 13/41 @entity0 (31.7%). The prevalence of @entity2 in males was 44.4% (28/63) and 33.3% (13/39) in females, while the most frequent combination of risk factors in @entity2 @entity0 was high blood pressure-high waist circumference-high levels of serum @entity5 (36.58%). Serum @entity5 >150 mg/dL is the most frequent component of the @entity2 both in well-nourished @entity0 and according to the duration of dialysis (58.53% for 0-5 years and 19.51% for >5 years on dialysis). @entity2 @entity0 had a better nutritional status and were on dialysis for less time than their @entity2 ( @entity2 ) counterparts. Actual or anamnestic cardiovascular events and @entity3 did not differ between the 2 groups. CONCLUSIONS: Our study provides new data concerning the prevalence of the @entity2 and the specific @entity0 characteristics in a hemodialysis population. The prevalence of @entity2 in hemodialysis @entity0 is high (40.19%) and seems to reflect a state of good nutrition compared to @entity0 without the @entity2 . Furthermore, the @entity2 is more common in the first years of dialysis (42.46+/-34.29 months) than later on (67.25+/-52.15 months) probably reflecting the long term consequences of the hemodialysis treatment. Our results also indicate that although @entity0 in the @entity2 group were well-nourished and for a shorter time on dialysis, they were not protected from @entity1 and @entity3 . Our study provides new data concerning both the prevalence of the @entity2 and a variety of @entity0 characteristics in a hemodialysis population. Further research and a larger number of @entity0 are required in order to clarify the precise role of this syndrome in @entity0 on MHD.

title: Prevalence of the XXXX in hemodialysis.

answer: @entity2


abstract: The ability of brewing @entity0 to flocculate is an important feature for brewing of qualitatively good beer. Flocculation involves two main cell wall structures, which are the flocculation proteins (flocculins) and mannans, to which these flocculins bind. Unfortunately, in practice, the flocculation ability may get lost after several repitches. Flow cytometry was employed to analyze @entity1 and @entity2 structures of the cell surface by application of fluorescent lectins. Validation of the expression of the flocculin genes Lg- @entity3 , @entity3 , @entity4 , and @entity5 was carried out using microarray techniques. SDS-PAGE, western blot, and ESI-MS/MS analyses served to isolate and determine @entity0 cell flocculins. @entity2 and @entity1 labeling with fluorescent lectins allowed differentiating powdery and flocculent @entity0 cells under laboratory conditions. Using microarray techniques and proteomics, the four flocculation genes Lg- @entity3 , @entity3 , @entity4 , @entity5 , and the protein Lg- @entity3 were identified as factors of major importance for flocculation. The expression of the genes was several times higher in flocculent @entity0 cells than in powdery ones. Flow cytometry is a fast and simple method to quantify the proportions of powdery and flocculent @entity0 cells in suspensions under defined cultivation conditions. However, differentiation under industrial conditions will require mRNA and protein expression profiling.

title: Prediction of flocculation ability of brewing XXXX inoculates by flow cytometry, proteome analysis, and mRNA profiling.

answer: @entity0


abstract: This report reviews the methods and goals of treatment of @entity4 ( @entity4 ), the most common @entity3 of the gastrointestinal tract. GISTs express @entity5 , which serves as an immunohistochemical diagnostic marker. Surgical excision is the definitive treatment for all primary GISTs greater than 2 cm without evidence of peritoneal seeding or @entity1 . Preoperative or intraoperative biopsy is not indicated except when the differential diagnosis includes another type of @entity2 . Resection may be performed by traditional open surgery or by laparoscopic or laparoscopy-assisted procedures. Regardless of the approach, oncological precautions must be strictly observed. @entity2 disruption is to be avoided at all costs; @entity2 enucleation leaves a @entity2 -seeded pseudocapsule behind and is considered insufficient. Because GISTs rarely metastasize through the lymphatics, routine lymphadenectomy is not indicated. The importance of achieving negative microscopic margins is controversial, although @entity0 who undergo incomplete microscopic resection may be at greater risk of locoregional recurrence. Other factors, such as @entity2 grade and size, may play a more significant role in predicting recurrence. Cases of advanced disease or involvement of adjacent structures should be evaluated on an individual basis by a multidisciplinary team.

title: Surgical management of XXXX : analysis of outcome with respect to surgical margins and technique.

answer: @entity4


abstract: INTRODUCTION: @entity5 ( @entity5 ) are a growing public health problem with important socio-economic effects in western countries. In the USA, 10 million @entity0 over 50 suffer from @entity2 . In these @entity0 , 1.5 million annual @entity3 have been registered, and 50% of these are vertebral compression. SOURCES OF DATA: We performed a comprehensive search of PubMed, Medline, Cochrane, CINAHL and Embase databases using various combinations of the keywords ' @entity2 ', ' @entity5 ', 'brace', 'bracing', 'orthosis', 'conservative management' and 'rehabilitation' over the years 1966-2011. All articles relevant to the subject were retrieved, and their bibliographies were hand searched for further references in the context of conservative management of @entity4 . AREAS OF AGREEMENT: Conservative management for @entity0 with @entity4 includes bed rest, @entity1 medication, physiotherapy and bracing. AREAS OF CONTROVERSY: A conservative management for @entity0 with @entity5 s has not been standardized. The utility of vertebral augmentation techniques has been questioned by recent randomized controlled trials. GROWING POINTS: Randomized controlled trials are being performed worldwide on vertebral augmentation techniques. AREAS TIMELY FOR DEVELOPING RESEARCH: Although spinal orthoses are commonly used for the management of @entity0 with @entity4 , in the literature there is only one randomized controlled trial on bracing for this condition. While the best conservative management for subjects with @entity5 s is not defined and standardized, no conclusions on the superiority of vertebral augmentation techniques over conservative management can be drawn.

title: XXXX : current concepts of conservative care.

answer: @entity4


abstract: PURPOSE: We previously identified in a single-center study a 76-gene prognostic signature for lymph node-negative (LNN) @entity0 @entity1 . The aim of this study was to validate this gene signature in an independent more diverse population of LNN @entity1 from multiple institutions. @entity1 AND METHODS: Using custom-designed DNA chips we analyzed the expression of the 76 genes in RNA of frozen @entity3 samples from 180 LNN @entity1 who did not receive adjuvant systemic treatment. RESULTS: In this independent validation, the 76-gene signature was highly informative in identifying @entity1 with distant @entity2 within 5 years (hazard ratio, [HR], 7.41; 95% CI, 2.63 to 20.9), even when corrected for traditional prognostic factors in multivariate analysis (HR, 11.36; 95% CI, 2.67 to 48.4). The actuarial 5- and 10-year distant @entity2 -free survival were 96% (95% CI, 89% to 99%) and 94% (95% CI, 83% to 98%), respectively, for the good profile group and 74% (95% CI, 64% to 81%) and 65% (53% to 74%), respectively for the poor profile group. The sensitivity for 5-yr distant @entity2 -free survival was 90%, and the specificity was 50%. The positive and negative predictive values were 38% (95% CI, 29% to 47%) and 94% (95% CI, 86% to 97%), respectively. The 76-gene signature was confirmed as a strong prognostic factor in subgroups of @entity4 receptor-positive @entity1 , pre- and postmenopausal @entity1 , and @entity1 with @entity3 sizes 20 mm or smaller. The subgroup of @entity1 with @entity4 receptor-negative @entity3 was considered too small to perform a separate analysis. CONCLUSION: Our data provide a strong methodologic and clinical multicenter validation of the predefined prognostic 76-gene signature in LNN @entity0 @entity1 .

title: Multicenter validation of a gene expression-based prognostic signature in lymph node-negative primary XXXX .

answer: @entity0


abstract: PURPOSE: Despite the progress that has been achieved, long-term survival rates in @entity0 with advanced @entity2 are still disappointing. One attempt to improve results could be the addition of non-cross-resistant drugs to @entity6 - @entity8 combination regimens. Anthracyclines were among the candidates for incorporation as a third drug into first-line regimens. @entity0 AND METHODS: We performed a prospectively randomized phase III study comparing @entity9 - @entity8 (TC; area under the curve 5/175 mg/m2, respectively) with @entity7 60 mg/m2 added to @entity10 ( @entity10 ) in previously untreated @entity0 with @entity2 . All drugs were administered intravenously on day 1 of a 3-week schedule for a planned minimum of six courses. RESULTS: Between November 1997 and February 2000, 1,282 @entity0 were randomly assigned to receive either TC (635 @entity0 ) or @entity10 (647 @entity0 ), respectively. Grade 3/4 hematologic and some nonhematologic @entity3 ( @entity5 /emesis, @entity1 , and @entity4 ) occurred significantly more frequently in the @entity10 arm. Accordingly, quality-of-life analysis showed inferiority of @entity10 versus TC. Median progression-free survival time was 18.4 months for the @entity10 arm and 17.9 months for the TC arm (hazard ratio [HR], 0.95; 95% CI, 0.83 to 1.07; P = .3342). Median overall survival time was 45.8 months for the @entity10 arm and 41.0 months for the TC arm (HR, 0.93; 95% CI, 0.81 to 1.08; P = .3652). Similar nonsignificant differences were observed when strata were analyzed separately. CONCLUSION: Addition of @entity7 to TC did not improve survival or time to treatment failure in @entity0 with @entity2 ; therefore, it cannot be recommended for clinical use in this population.

title: Addition of XXXX as a third drug to @entity9 - @entity8 in first-line treatment of advanced @entity2 : a prospectively randomized gynecologic cancer intergroup trial by the Arbeitsgemeinschaft Gynaekologische Onkologie @entity2 Study Group and the Groupe d'Investigateurs Nationaux pour l'Etude des Cancers Ovariens.

answer: @entity7


abstract: PURPOSE: Despite the progress that has been achieved, long-term survival rates in @entity0 with advanced @entity2 are still disappointing. One attempt to improve results could be the addition of non-cross-resistant drugs to @entity6 - @entity8 combination regimens. Anthracyclines were among the candidates for incorporation as a third drug into first-line regimens. @entity0 AND METHODS: We performed a prospectively randomized phase III study comparing @entity9 - @entity8 (TC; area under the curve 5/175 mg/m2, respectively) with @entity7 60 mg/m2 added to @entity10 ( @entity10 ) in previously untreated @entity0 with @entity2 . All drugs were administered intravenously on day 1 of a 3-week schedule for a planned minimum of six courses. RESULTS: Between November 1997 and February 2000, 1,282 @entity0 were randomly assigned to receive either TC (635 @entity0 ) or @entity10 (647 @entity0 ), respectively. Grade 3/4 hematologic and some nonhematologic @entity3 ( @entity5 /emesis, @entity1 , and @entity4 ) occurred significantly more frequently in the @entity10 arm. Accordingly, quality-of-life analysis showed inferiority of @entity10 versus TC. Median progression-free survival time was 18.4 months for the @entity10 arm and 17.9 months for the TC arm (hazard ratio [HR], 0.95; 95% CI, 0.83 to 1.07; P = .3342). Median overall survival time was 45.8 months for the @entity10 arm and 41.0 months for the TC arm (HR, 0.93; 95% CI, 0.81 to 1.08; P = .3652). Similar nonsignificant differences were observed when strata were analyzed separately. CONCLUSION: Addition of @entity7 to TC did not improve survival or time to treatment failure in @entity0 with @entity2 ; therefore, it cannot be recommended for clinical use in this population.

title: Addition of @entity7 as a third drug to XXXX - @entity8 in first-line treatment of advanced @entity2 : a prospectively randomized gynecologic cancer intergroup trial by the Arbeitsgemeinschaft Gynaekologische Onkologie @entity2 Study Group and the Groupe d'Investigateurs Nationaux pour l'Etude des Cancers Ovariens.

answer: @entity9


abstract: PURPOSE: Despite the progress that has been achieved, long-term survival rates in @entity0 with advanced @entity2 are still disappointing. One attempt to improve results could be the addition of non-cross-resistant drugs to @entity6 - @entity8 combination regimens. Anthracyclines were among the candidates for incorporation as a third drug into first-line regimens. @entity0 AND METHODS: We performed a prospectively randomized phase III study comparing @entity9 - @entity8 (TC; area under the curve 5/175 mg/m2, respectively) with @entity7 60 mg/m2 added to @entity10 ( @entity10 ) in previously untreated @entity0 with @entity2 . All drugs were administered intravenously on day 1 of a 3-week schedule for a planned minimum of six courses. RESULTS: Between November 1997 and February 2000, 1,282 @entity0 were randomly assigned to receive either TC (635 @entity0 ) or @entity10 (647 @entity0 ), respectively. Grade 3/4 hematologic and some nonhematologic @entity3 ( @entity5 /emesis, @entity1 , and @entity4 ) occurred significantly more frequently in the @entity10 arm. Accordingly, quality-of-life analysis showed inferiority of @entity10 versus TC. Median progression-free survival time was 18.4 months for the @entity10 arm and 17.9 months for the TC arm (hazard ratio [HR], 0.95; 95% CI, 0.83 to 1.07; P = .3342). Median overall survival time was 45.8 months for the @entity10 arm and 41.0 months for the TC arm (HR, 0.93; 95% CI, 0.81 to 1.08; P = .3652). Similar nonsignificant differences were observed when strata were analyzed separately. CONCLUSION: Addition of @entity7 to TC did not improve survival or time to treatment failure in @entity0 with @entity2 ; therefore, it cannot be recommended for clinical use in this population.

title: Addition of @entity7 as a third drug to @entity9 - @entity8 in first-line treatment of advanced XXXX : a prospectively randomized gynecologic cancer intergroup trial by the Arbeitsgemeinschaft Gynaekologische Onkologie @entity2 Study Group and the Groupe d'Investigateurs Nationaux pour l'Etude des Cancers Ovariens.

answer: @entity2


abstract: PURPOSE: Despite the progress that has been achieved, long-term survival rates in @entity0 with advanced @entity2 are still disappointing. One attempt to improve results could be the addition of non-cross-resistant drugs to @entity6 - @entity8 combination regimens. Anthracyclines were among the candidates for incorporation as a third drug into first-line regimens. @entity0 AND METHODS: We performed a prospectively randomized phase III study comparing @entity9 - @entity8 (TC; area under the curve 5/175 mg/m2, respectively) with @entity7 60 mg/m2 added to @entity10 ( @entity10 ) in previously untreated @entity0 with @entity2 . All drugs were administered intravenously on day 1 of a 3-week schedule for a planned minimum of six courses. RESULTS: Between November 1997 and February 2000, 1,282 @entity0 were randomly assigned to receive either TC (635 @entity0 ) or @entity10 (647 @entity0 ), respectively. Grade 3/4 hematologic and some nonhematologic @entity3 ( @entity5 /emesis, @entity1 , and @entity4 ) occurred significantly more frequently in the @entity10 arm. Accordingly, quality-of-life analysis showed inferiority of @entity10 versus TC. Median progression-free survival time was 18.4 months for the @entity10 arm and 17.9 months for the TC arm (hazard ratio [HR], 0.95; 95% CI, 0.83 to 1.07; P = .3342). Median overall survival time was 45.8 months for the @entity10 arm and 41.0 months for the TC arm (HR, 0.93; 95% CI, 0.81 to 1.08; P = .3652). Similar nonsignificant differences were observed when strata were analyzed separately. CONCLUSION: Addition of @entity7 to TC did not improve survival or time to treatment failure in @entity0 with @entity2 ; therefore, it cannot be recommended for clinical use in this population.

title: Addition of @entity7 as a third drug to @entity9 - @entity8 in first-line treatment of advanced @entity2 : a prospectively randomized gynecologic cancer intergroup trial by the Arbeitsgemeinschaft Gynaekologische Onkologie XXXX Study Group and the Groupe d'Investigateurs Nationaux pour l'Etude des Cancers Ovariens.

answer: @entity2


abstract: PURPOSE: Despite the progress that has been achieved, long-term survival rates in @entity0 with advanced @entity2 are still disappointing. One attempt to improve results could be the addition of non-cross-resistant drugs to @entity6 - @entity8 combination regimens. Anthracyclines were among the candidates for incorporation as a third drug into first-line regimens. @entity0 AND METHODS: We performed a prospectively randomized phase III study comparing @entity9 - @entity8 (TC; area under the curve 5/175 mg/m2, respectively) with @entity7 60 mg/m2 added to @entity10 ( @entity10 ) in previously untreated @entity0 with @entity2 . All drugs were administered intravenously on day 1 of a 3-week schedule for a planned minimum of six courses. RESULTS: Between November 1997 and February 2000, 1,282 @entity0 were randomly assigned to receive either TC (635 @entity0 ) or @entity10 (647 @entity0 ), respectively. Grade 3/4 hematologic and some nonhematologic @entity3 ( @entity5 /emesis, @entity1 , and @entity4 ) occurred significantly more frequently in the @entity10 arm. Accordingly, quality-of-life analysis showed inferiority of @entity10 versus TC. Median progression-free survival time was 18.4 months for the @entity10 arm and 17.9 months for the TC arm (hazard ratio [HR], 0.95; 95% CI, 0.83 to 1.07; P = .3342). Median overall survival time was 45.8 months for the @entity10 arm and 41.0 months for the TC arm (HR, 0.93; 95% CI, 0.81 to 1.08; P = .3652). Similar nonsignificant differences were observed when strata were analyzed separately. CONCLUSION: Addition of @entity7 to TC did not improve survival or time to treatment failure in @entity0 with @entity2 ; therefore, it cannot be recommended for clinical use in this population.

title: Addition of @entity7 as a third drug to @entity9 - XXXX in first-line treatment of advanced @entity2 : a prospectively randomized gynecologic cancer intergroup trial by the Arbeitsgemeinschaft Gynaekologische Onkologie @entity2 Study Group and the Groupe d'Investigateurs Nationaux pour l'Etude des Cancers Ovariens.

answer: @entity8


abstract: @entity2 of the newborn is defined as the failure of the normal circulatory transition that occurs after birth. It is a syndrome characterized by marked @entity2 that causes @entity4 and right-to-left extra-pulmonary shunting of blood. In the treatment of @entity2 of the newborn, the goal is to increase @entity1 flow to the baby's organs to prevent serious health problems. Treatment may include medication, mechanical ventilation and respiratory therapy. We performed a retrospective, descriptive and transversal study to investigate the prevalence and treatment of @entity7 @entity0 with @entity2 who were admitted at the Hospital del Ni  o @entity3 from 2004 to 2008. Data, collected from hospital charts, included demographic, clinical course and use of medication. A total of 38 @entity0 were included (prevalence of 5.7%). The average age of @entity0 was 8.4 +/- 1.4 days. The mortality rate was 42.1%. Data were collected and 45 different drugs were given to the pediatric @entity0 . The median number of drugs/inpatient was 8.3 (1-18). The therapeutic class most prescribed was anti-infective (29.9% of all the prescriptions), followed by cardiovascular and renal drugs (26.4% of all the prescriptions) and gastrointestinal agents (14.6% of all the prescriptions). @entity8 was the drug most commonly used, followed by @entity5 and @entity6 . We found a high mortality rate and as in many studies, the therapeutic class most used were anti-infectives.

title: Prevalence and treatment of XXXX in the newborn in a Mexican pediatric hospital.

answer: @entity2


abstract: OBJECTIVE: To compare the incidence of @entity3 ( @entity3 ) in @entity0 ventilated in intensive care by means of circuits humidified with a hygroscopic heat-and-moisture exchanger with a bacterial viral filter (HME) or hot-water humidification with a heater wire in both inspiratory and expiratory circuit limbs (DHW) or the inspiratory limb only (SHW). DESIGN: A prospective, randomized trial. SETTING: A metropolitan teaching hospital's general intensive care unit. @entity0 : Three hundred eighty-one @entity0 requiring a minimum period of mechanical ventilation of 48 hrs. INTERVENTIONS: @entity0 were randomized to humidification with use of an HME (n=190), SHW (n=94), or DHW (n=97). MEASUREMENTS AND MAIN RESULTS: Study end points were @entity3 diagnosed on the basis of @entity2 Score (CPIS) (), HME resistance after 24 hrs of use, endotracheal tube resistance, and HME use per @entity0 . @entity3 occurred with similar frequency in all groups (13%, HME; 14%, DHW; 10%, SHW; p=0.61) and was predicted only by current smoking (adjusted odds ratio [AOR], 2.1; 95% confidence interval [CI], 1.1-3.9; p=.03) and ventilation days (AOR, 1.05; 95% CI, 1.0-1.2; p=.001); @entity3 was less likely for @entity0 with an admission diagnosis of @entity1 (AOR, 0.40; 95% CI, 0.4-0.2; p=.04). HME resistance after 24 hrs of use measured at a gas flow of 50 L/min was 0.9 cm @entity4 (0.4-2.9). Endotracheal tube resistance was similar for all three groups (16-19 cm @entity4 min/L; p=.2), as were suction frequency, secretion thickness, and blood on suctioning (p=.32, p=.06, and p=.34, respectively). The HME use per @entity0 per day was 1.13. CONCLUSIONS: Humidification technique does not influence either @entity3 incidence or secretion characteristics, but HMEs may have air-flow resistance higher than manufacturer specifications after 24 hrs of use.

title: Double-heater-wire circuits and heat-and-moisture exchangers and the risk of XXXX .

answer: @entity3


abstract: The cestodes constitute important but understudied @entity0 and veterinary parasites. Their surfaces are rich in @entity3 , on which very little structural information is available. The tissue-dwelling larva (hydatid cyst) of the cestode @entity7 is outwardly protected by a massive layer of @entity1 -rich extracellular matrix, termed the laminated layer. The @entity6 composition of this layer suggests that its major @entity1 components are exclusively mucin-type O-glycans. We have purified these glycans after their release from the crude laminated layer and obtained by MS and NMR the complete structure of 10 of the most abundant components. The structures, between two and six residues in length, encompass a limited number of biosynthetic motifs. The mucin cores 1 and 2 are either nondecorated or elongated by a chain of Galpbeta1-3 residues. This chain can be capped by a single Galpalpha1-4 residue, such capping becoming more dominant with increasing chain size. In addition, the core 2 @entity5 residue is in cases substituted with the disaccharide Galpalpha1-4Galpbeta1-4, giving rise to the blood P(1)-antigen motif. Larger, also related, glycans exist, reaching at least 18 residues in size. The glycans described are related but larger than those previously described from an @entity2 mucin [Hulsmeier, A. J., et al. (2002) J. Biol. Chem. 277, 5742-5748]. Our results reveal that the @entity7 cyst exposes to the host only a few different major @entity1 motifs. These motifs are composed essentially of @entity4 units and include the elongation by (Galpbeta1-3)(n) and the capping by Galpalpha1-4, novel in animal mucin-type O-glycans.

title: The major surface @entity3 of the XXXX cyst: mucin-type O-glycans decorated by novel @entity4 -based structures.

answer: @entity7


abstract: The cestodes constitute important but understudied @entity0 and veterinary parasites. Their surfaces are rich in @entity3 , on which very little structural information is available. The tissue-dwelling larva (hydatid cyst) of the cestode @entity7 is outwardly protected by a massive layer of @entity1 -rich extracellular matrix, termed the laminated layer. The @entity6 composition of this layer suggests that its major @entity1 components are exclusively mucin-type O-glycans. We have purified these glycans after their release from the crude laminated layer and obtained by MS and NMR the complete structure of 10 of the most abundant components. The structures, between two and six residues in length, encompass a limited number of biosynthetic motifs. The mucin cores 1 and 2 are either nondecorated or elongated by a chain of Galpbeta1-3 residues. This chain can be capped by a single Galpalpha1-4 residue, such capping becoming more dominant with increasing chain size. In addition, the core 2 @entity5 residue is in cases substituted with the disaccharide Galpalpha1-4Galpbeta1-4, giving rise to the blood P(1)-antigen motif. Larger, also related, glycans exist, reaching at least 18 residues in size. The glycans described are related but larger than those previously described from an @entity2 mucin [Hulsmeier, A. J., et al. (2002) J. Biol. Chem. 277, 5742-5748]. Our results reveal that the @entity7 cyst exposes to the host only a few different major @entity1 motifs. These motifs are composed essentially of @entity4 units and include the elongation by (Galpbeta1-3)(n) and the capping by Galpalpha1-4, novel in animal mucin-type O-glycans.

title: The major surface XXXX of the @entity7 cyst: mucin-type O-glycans decorated by novel @entity4 -based structures.

answer: @entity3


abstract: The cestodes constitute important but understudied @entity0 and veterinary parasites. Their surfaces are rich in @entity3 , on which very little structural information is available. The tissue-dwelling larva (hydatid cyst) of the cestode @entity7 is outwardly protected by a massive layer of @entity1 -rich extracellular matrix, termed the laminated layer. The @entity6 composition of this layer suggests that its major @entity1 components are exclusively mucin-type O-glycans. We have purified these glycans after their release from the crude laminated layer and obtained by MS and NMR the complete structure of 10 of the most abundant components. The structures, between two and six residues in length, encompass a limited number of biosynthetic motifs. The mucin cores 1 and 2 are either nondecorated or elongated by a chain of Galpbeta1-3 residues. This chain can be capped by a single Galpalpha1-4 residue, such capping becoming more dominant with increasing chain size. In addition, the core 2 @entity5 residue is in cases substituted with the disaccharide Galpalpha1-4Galpbeta1-4, giving rise to the blood P(1)-antigen motif. Larger, also related, glycans exist, reaching at least 18 residues in size. The glycans described are related but larger than those previously described from an @entity2 mucin [Hulsmeier, A. J., et al. (2002) J. Biol. Chem. 277, 5742-5748]. Our results reveal that the @entity7 cyst exposes to the host only a few different major @entity1 motifs. These motifs are composed essentially of @entity4 units and include the elongation by (Galpbeta1-3)(n) and the capping by Galpalpha1-4, novel in animal mucin-type O-glycans.

title: The major surface @entity3 of the @entity7 cyst: mucin-type O-glycans decorated by novel XXXX -based structures.

answer: @entity4


abstract: Invasive @entity3 (IFIs) are being increasingly recognized as a major threat in @entity10 adult and paediatric @entity0 . They can range widely in severity and can be life threatening in some @entity0 . Candida and Aspergillus species are the most common causes of IFIs, but other @entity4 and filamentous fungi are emerging pathogens. @entity11 , the most significant pathogenic species, is seen in almost all of the 17% of @entity0 treated in the @entity5 ( @entity5 ) who develop IFIs, and is associated with significant morbidity and mortality. Non-albicans spp. are becoming more common, particularly in @entity7 @entity0 and those on existing @entity14 therapy. Early diagnosis is challenging due to delays in, and low sensitivity of, confirmatory blood cultures, and difficulty in discriminating colonization from @entity1 . Once diagnosed, early initiation of appropriate antifungal therapy is essential for reducing morbidity and mortality. @entity8 deoxycholate and @entity17 , once standard therapy, have been largely superseded in the @entity5 by broad-spectrum azoles, liposomal @entity8 and the newer @entity13 agents with improved efficacy/tolerability profiles. The @entity12 ( @entity18 , @entity6 and @entity19 ) exhibit fungicidal activity against Candida spp. and fungistatic activity against Aspergillus spp. Echinocandins have demonstrated clinical efficacy, broad spectrum of activity and favourable pharmacological properties, and are, therefore, likely to replace @entity9 as the initial antifungal agent of choice among @entity10 @entity0 . Current evidence supports @entity13 empirical therapy for candidaemia or @entity1 in @entity5 @entity0 with or without @entity7 , and as rescue therapy in @entity0 with life-threatening IFIs caused by strains resistant to other antifungals. Anidulafungin represents a new advance in the treatment of IFIs and is approved for treatment of candidaemia, @entity15 , @entity2 and @entity16 .

title: Invasive XXXX : the challenge continues.

answer: @entity3


abstract: OBJECT: The object of this study was to compare the recurrence rates of @entity4 after @entity2 fenestration combined with Gamma Knife surgery (GKS) and after subtotal resection (STR) combined with GKS. METHODS: The records of 27 @entity0 (age range 3-66 years) with @entity4 that were treated surgically or neuroendoscopically before GKS between January 2000 and December 2007 were reviewed to compare recurrence rates. The @entity0 were divided into 2 groups: Group 1 (13 @entity0 ) received the neuroendoscopic procedure before GKS, and Group 2 (14 @entity0 ) received an STR followed by GKS. @entity1 volumes, radiation doses, @entity3 , endocrine levels, and recurrences were compared between the 2 groups. @entity0 with solid @entity1 and those who underwent complete resection were excluded from the study. RESULTS: The recurrence rate for Group 1 was higher than that of Group 2 (p = 0.046). The radiation dose near the optic chiasm was higher in Group 1 (p = 0.021) than in Group 2. However, endocrine function was better preserved in Group 1 than in Group 2. CONCLUSIONS: This investigation confirms that STR followed by GKS results in a lower recurrence rate than neuroendoscopy and GKS. Neuroendoscopy and GKS, however, results in a better preservation of endocrine function. These results suggest that a generalized multimodal approach including endoscopic fenestration in addition to GKS is hindered by higher recurrence rates.

title: Recurrence rates after neuroendoscopic fenestration and Gamma Knife surgery in comparison with subtotal resection and Gamma Knife surgery for the treatment of XXXX .

answer: @entity4


abstract: Immune responses against adenovirus (Ad) vectors pose a possible concern for the outcome of treatment efficacy. To address the role of preexisting immunity in oncolytic Ad vector antitumor efficacy following intratumoral injection of vector as well as @entity0 -to-tissue spread of the vector, we employed the @entity2 model. These animals are immunocompetent, and their @entity0 and tissues are permissive for replication of Ad type 5 (Ad5). We used the @entity1 protein-overexpressing Ad5-based vector INGN 007. @entity0 were established in groups of hamsters that were or were not immunized with Ad5. Half of the hamsters in these groups were immunosuppressed with @entity3 . For all groups, @entity0 injected with INGN 007 grew significantly more slowly than those injected with buffer. Under immunocompetent conditions, there was no significant effect of preexisting immunity on vector antitumor efficacy. Soon after the @entity0 in na  ve animals were injected with vector, the hamsters developed neutralizing antibody (NAb) and the difference in NAb titers between the na  ve and immunized groups diminished. Under immunosuppressed conditions, preexisting NAb did significantly reduce vector efficacy. Thus, NAb do reduce vector efficacy to some extent, but immunosuppression is required to observe the effect. Regarding vector toxicity, there was spillover of vector from the @entity0 to the liver and lungs in na  ve immunocompetent hamsters, and this was nearly eliminated in the immunized hamsters. Thus, preexisting immunity to Ad5 does not affect INGN 007 antitumor efficacy following intratumoral injection, but immunity prevents vector spillover from the @entity0 to the liver and lungs.

title: Effect of preexisting immunity on oncolytic adenovirus vector INGN 007 antitumor efficacy in immunocompetent and immunosuppressed XXXX .

answer: @entity2


abstract: AIM: This study aimed to evaluate the immediate and long-term effects of a 12 week problem-solving (PS) counseling program to facilitate intensified walking with machinery monitoring on @entity0 with @entity1 in Korea. METHODS: The study used a quasi-experimental design. The @entity0 were 57 @entity0 with @entity1 from three endocrinology or internal medicine clinics in an urban city of South Korea. Moderate-intensity walking and PS counseling were recommended to both groups. The difference between the two groups was whether the intensity of the exercise was monitored by an ambulatory heart rate monitor (experimental group) or was self-regulated (comparison group). Those programs were evaluated in relation to BMI, glycemic control (blood @entity3 level, glycosylated hemoglobin [HbA1c]), a vascular complication index (total @entity2 , high-density lipoprotein @entity2 , low-density lipoprotein @entity2 , @entity4 , tissue plasminogen activator [ @entity6 ], @entity5 [ @entity5 ], Parma Cardiovascular Risk Index), and coping strategies at 3 and 6 months. RESULTS: The experimental group members showed dramatic decreases in their @entity3 and HbA1c levels at 3 months. The values of @entity6 decreased significantly at baseline, compared to at 3 months. The levels of @entity5 continuously declined and the Parma Cardiovascular Risk Index score did not change significantly from baseline to at 3 months, but showed significant effects at 6 months. CONCLUSION: A combined program of intensified walking, using a heart rate monitor, with PS counseling is more helpful to prevent complications than self-regulated exercise for @entity0 with type 2 @entity1 in Korea.

title: Effects of a problem-solving counseling program to facilitate intensified walking on Koreans with type 2 XXXX .

answer: @entity1


abstract: BACKGROUND AND OBJECTIVES: @entity0 with primary @entity3 ( @entity3 ) who are resistant to standard therapy are at high risk for progressive @entity4 . Prevention of @entity1 represents a promising strategy to slow or halt kidney function decline. This paper presents the results of a Phase I clinical trial of @entity5 , a @entity6 , that exerts antifibrotic effects in animal models of @entity3 . The primary goal was assessment of safety, tolerability, and pharmacokinetics (PK) of @entity5 . DESIGN, SETTING, @entity0 , _ MEASUREMENTS: Eleven @entity0 , including eight @entity0 / @entity0 and three @entity0 / @entity0 , with mean age 15 +/- 6 yr and estimated GFR 131 +/- 62 ml/min/1.73 m(2), received @entity5 , 3 mg/m(2)/d for 16 wk. PK was assessed twice, after the initial dose and after attaining steady state, in a General Clinical Research Center. RESULTS: There were no serious adverse events or @entity2 . @entity5 was well tolerated by all @entity0 , as judged by the Treatment Satisfaction Questionnaire for Medication. The PK studies indicated that the area under the curve was decreased by 40 to 50% and oral clearance of @entity5 was increased by 250 to 300% in @entity0 with resistant @entity3 compared with healthy controls and @entity0 with @entity4 . CONCLUSIONS: @entity5 therapy was safe and well tolerated. PK assessment of potential novel therapies for resistant @entity3 is necessary to define appropriate dosing regimens. There is rationale to evaluate the efficacy of @entity5 as an antifibrotic agent for resistant @entity3 in Phase II/III clinical trials.

title: Phase I trial of @entity5 in XXXX : I. Report of the FONT Study Group.

answer: @entity3


abstract: BACKGROUND AND OBJECTIVES: @entity0 with primary @entity3 ( @entity3 ) who are resistant to standard therapy are at high risk for progressive @entity4 . Prevention of @entity1 represents a promising strategy to slow or halt kidney function decline. This paper presents the results of a Phase I clinical trial of @entity5 , a @entity6 , that exerts antifibrotic effects in animal models of @entity3 . The primary goal was assessment of safety, tolerability, and pharmacokinetics (PK) of @entity5 . DESIGN, SETTING, @entity0 , _ MEASUREMENTS: Eleven @entity0 , including eight @entity0 / @entity0 and three @entity0 / @entity0 , with mean age 15 +/- 6 yr and estimated GFR 131 +/- 62 ml/min/1.73 m(2), received @entity5 , 3 mg/m(2)/d for 16 wk. PK was assessed twice, after the initial dose and after attaining steady state, in a General Clinical Research Center. RESULTS: There were no serious adverse events or @entity2 . @entity5 was well tolerated by all @entity0 , as judged by the Treatment Satisfaction Questionnaire for Medication. The PK studies indicated that the area under the curve was decreased by 40 to 50% and oral clearance of @entity5 was increased by 250 to 300% in @entity0 with resistant @entity3 compared with healthy controls and @entity0 with @entity4 . CONCLUSIONS: @entity5 therapy was safe and well tolerated. PK assessment of potential novel therapies for resistant @entity3 is necessary to define appropriate dosing regimens. There is rationale to evaluate the efficacy of @entity5 as an antifibrotic agent for resistant @entity3 in Phase II/III clinical trials.

title: Phase I trial of XXXX in @entity3 : I. Report of the FONT Study Group.

answer: @entity5


abstract: @entity5 -3-kinase (PI3K)-Akt pathway is essential for conferring cardioprotection in response to ischaemic preconditioning (IPC) stimulus. However, the role of the individual Akt isoforms expressed in the heart in mediating the protective response to IPC is unknown. In this study, we investigated the specific contribution of @entity3 and @entity4 in cardioprotection against ischaemia-reperfusion (I-R) injury. @entity1 deficient in @entity3 or @entity4 were subjected to in vivo regional @entity2 for 30 min. followed by reperfusion for 2 hrs with or without a prior IPC stimulus. Our results show that @entity1 deficient in @entity3 were resistant to protection with either one or three cycles of IPC stimulus (42.7    6.5% control versus 38.5    1.9% 1    IPC, N = 6, @entity7 ; 41.4    6.3% control versus 32.4    3.2% 3    IPC, N = 10, @entity7 ). Western blot analysis, performed on heart samples taken from @entity3 (-/-) @entity1 subjected to IPC, revealed an impaired phosphorylation of @entity6 , a downstream effector of Akt, as well as @entity8 , the parallel component of the reperfusion injury salvage kinase pathway. @entity4 (-/-) @entity1 , which exhibit a @entity0 phenotype, however, were amenable to protection with three but not one cycle of IPC (46.4    5.6% control versus 35.9    5.0% in 1    IPC, N = 6, @entity7 ; 47.0    6.0% control versus 30.8    3.3% in 3    IPC, N = 6; *P = 0.039). @entity3 but not @entity4 is essential for mediating a protective response to an IPC stimulus. Impaired activation of @entity6 and @entity8 might be responsible for the lack of protective response to IPC in @entity3 (-/-) @entity1 . The rise in threshold for protection in @entity4 (-/-) @entity1 might be due to their @entity0 phenotype.

title: The XXXX isoform is an essential mediator of ischaemic preconditioning.

answer: @entity3


abstract: BACKGROUND: Transmission-blocking vaccines (TBVs) have been considered an important strategy for disrupting the @entity0 transmission cycle, especially for @entity2 @entity0 , which undergoes gametocytogenesis earlier during infection. Pvs25 and Pvs28 are transmission-blocking vaccine candidates for @entity2 @entity0 . Assessment of genetic diversity of the vaccine candidates will provide necessary information for predicting the performance of vaccines, which will guide us during the development of @entity0 vaccines. RESULTS: We sequenced the coding regions of pvs25 and pvs28 from 30 @entity2 isolates from Yunnan Province, identifying five @entity1 haplotypes of Pvs25 and seven @entity1 haplotypes of Pvs28. Among a total of four mutant residues, the predominant haplotype of Pvs25 only had the @entity3 substitution. For Pvs28, a total of eight @entity1 substitutions were identified. The predominant haplotype of Pvs28 had two substitution at positions 52 ( @entity4 ) and 140 ( @entity5 ) with 5-6 GSGGE/D tandem repeats at the end of fourth EGF-like domain. Most @entity1 substitutions were common with previous reports from South Asian isolates. Although the nucleotide diversity of pvs28 (   = 0.0034    0.0012) was significantly higher than pvs25 (   = 0.0013    0.0009), it was still conserved when compared with the blood stage vaccine candidates. CONCLUSIONS: Genetic analysis revealed limited genetic diversity of pvs25 and pvs28, suggesting antigenic diversity may not be a particular problem for Sal I based TBVs in most @entity2 -endemic areas of China.

title: Genetic diversity of transmission-blocking vaccine candidates Pvs25 and Pvs28 in XXXX isolates from Yunnan Province, China.

answer: @entity2


abstract: BACKGROUND: Two inflammatory disorders, @entity3 , cosegregate in populations, suggesting a common genetic origin. Since both diseases are associated with the HLA class II genes on chromosome 6p21, we tested whether non-HLA loci are shared. METHODS: We evaluated the association between type 1 @entity1 and eight loci related to the risk of @entity2 by genotyping and statistical analyses of DNA samples from 8064 @entity0 with type 1 @entity1 , 9339 control subjects, and 2828 families providing 3064 parent- @entity0 trios (consisting of an affected @entity0 and both biologic parents). We also investigated 18 loci associated with type 1 @entity1 in 2560 @entity0 with @entity2 and 9339 control subjects. RESULTS: Three @entity2 loci-- @entity10 on chromosome 1q31, @entity11 on chromosome 2q12, and @entity12 on chromosome 6q25--were associated with type 1 @entity1 (P<1.00x10(-4)). The 32-bp insertion-deletion variant on chromosome 3p21 was newly identified as a type 1 @entity1 locus (P=1.81x10(-8)) and was also associated with @entity2 , along with @entity9 on chromosome 18p11 and @entity6 on chromosome 2q33, bringing the total number of loci with evidence of a shared association to seven, including @entity13 on chromosome 12q24. The effects of the @entity11 and @entity12 alleles confer protection in type 1 @entity1 and susceptibility in @entity2 . Loci with distinct effects in the two diseases included INS on chromosome 11p15, @entity4 on chromosome 10p15, and @entity7 on chromosome 1p13 in type 1 @entity1 and @entity8 on 3q25 and LPP on 3q28 in @entity2 . CONCLUSIONS: A genetic susceptibility to both @entity3 shares common alleles. These data suggest that common biologic mechanisms, such as @entity5 and intolerance to dietary antigens, may be etiologic features of both diseases.

title: Shared and distinct genetic variants in XXXX .

answer: @entity3


abstract: An important objective of @entity2 modeling is to predict the progression of @entity1 so as to provide guidance about the best possible medical treatment to halt or slow the @entity1 's growth. Such computer models also provide a deeper insight into the physiology of @entity1 . In addition, one can study various what-if scenarios, for instance, investigating the response of @entity1 following the administration of a drug or a variety of drugs. Abrupt changes in growth rate can also be important for surgical decision-making. Despite increased interest in modeling techniques, relatively little progress has been made in improving such technologies. One problem is the limited data available from @entity0 , typically 1 to 3 MRI (magnetic resonance imaging) sessions, from which one has to extrapolate the type of @entity1 so as to successfully predict its evolution over time. Here, the biological and clinical aspects of @entity1 growth and treatment with surgery, radiotherapy and drugs are discussed in the light of a @entity0 with a @entity2 showing accelerated growth over time. Then, the contributions of mathematical modeling of @entity1 growth and effects of treatment are presented. Current @entity1 growth models can be roughly divided in three main categories, (i) cellular and microscopic models that emphasize isolated cell behavior, (ii) macroscopic models that concentrate on the development of cell density over time, and (iii) hybrid approaches that contain elements of both microscopic and macroscopic models. The mathematical theory that underlies these simulation methods is remarkably similar to the physical theory that forms the basis of protein modeling and molecular mechanics tools. A severe limitation of current models is that they are in fact not @entity0 -specific at all.

title: Computer modeling of XXXX growth.

answer: @entity2


abstract: INTRODUCTION: @entity6 ( @entity6 ) of the sinonasal tract is a rare disease. OBJECTIVE: Report a descriptive study of a relatively large cohort of @entity6 of the nasal cavity and paranasal sinuses. METHOD: The medical records of 21 @entity0 presenting with nasal and paranasal @entity6 to various French hospitals, from 1989 to 2003, were analysed to determine the clinical features and current treatment of the disease. RESULTS: @entity0 data were obtained from eight French hospitals. Twelve of the @entity0 were male and nine were female, with a mean age at presentation of 55 years (range: 27 to 79 years). @entity0 ' staging for nasal cavity malignancy was: T1, four; T2, three; T3, one; T4, 13; N0, 18; N2, three; M0, 20; and M1, one. None of the @entity0 suffered from @entity6 of the sinonasal tract with ectopic hormone production. Immunohistochemistry proved useful for diagnosis in 20 cases. Twelve cases were positive for @entity7 for chromogranin, eight for neuron-specific enolase and 11 for neuron-specific synaptophysin. One @entity0 had an @entity3 and an @entity4 associated with @entity5 . @entity0 underwent surgery (11 cases), radiotherapy (14 cases) and chemotherapy (12 cases). Recurrence occurred in 10 cases. Five @entity0 had visceral metastases or cervical lymph node involvement. Nine of the @entity0 died within four years of onset of the disease. CONCLUSION: @entity6 of the sinonasal tract is an uncommon @entity1 with @entity2 clinical behaviour. Recurrence is frequent and the prognosis is poor. However, the current treatment of these neuroendocrine @entity1 varies widely.

title: XXXX and paranasal sinuses.

answer: @entity6


abstract: The introduction of oral agents for the treatment of @entity2 ( @entity2 ) has revolutionized the treatment of @entity0 with erection problems of all severities and etiologies. @entity5 , available on the world market since 1998 was joined in 2003 by @entity7 and @entity4 as effective save and reliable oral agents. While these agents share the method of action in common and are all contraindicated with @entity3 medications, these are differences among the three agents. @entity5 has the longest @entity0 experience and the most robust data confirming its activity, safety and tolerability. It has recently been released for use in @entity1 as well as @entity2 . @entity4 , the most biochemically potent of the molecules has also been demonstrated to be effective in @entity0 with severe @entity2 and in some @entity0 failing @entity5 . @entity7 is unique in its longer half life and is also tolerable, safe and effective in all severities and etiologies of @entity2 . Tadalafil is also unique in its inhibition of PDE 11, a characteristic of unknown but probably negligible importance. Newer data have also suggested that these agents may be helpful in the treatment of lower urinary tract symptoms. Since the introduction of @entity5 in 1998, @entity2 has been effectively treated with oral medications. The recent addition of @entity4 and tadalafil to the market has increased the number of phosphodiesterase type 5 inhibitors ( @entity6 ) to three agents used throughout the world. Each of these agents has similar mechanism of action, but has distinct differences. All three drugs in this class have similar pharmacokinetic and pharmacodynamic profiles and each is effective for @entity0 with @entity2 of all ages, severities and etiologies. While there are clear pharmacokinetic and pharmacodynamic differences amongst these agents, clinical differences are somewhat more difficult to identify. Indeed the data of preference trials, head to head clinical trials, and selection trials are few. The differences in pharmacokinetics while having distinct advantages in marketing each drug may be difficult for clinicians and @entity0 to identify. With the lack of data and well done clinical trials, it is difficult for the clinician to differentiate amongst the three agents and to select a @entity6 inhibitor for a specific @entity2 @entity0 or a specific agent to switch to if an initial @entity6 agent is unsuccessful or poorly tolerated. This discussion summarizes some of the current data on @entity6 inhibitors and their efficacy, safety, and use in other conditions.

title: XXXX inhibitors: are there differences?

answer: @entity6


abstract: OBJECTIVE: To assess the methodological quality of randomized controlled trials ( @entity1 ) of medical and surgical therapy in @entity0 with arthroplasty. METHODS: We conducted a Medline database search for all arthroplasty @entity1 from 1997 and 2006. The quality of the methods of all eligible @entity1 was assessed by a trained abstractor. We used a checklist of trial quality characteristics, and the overall trial quality was assessed by 3 scales: Jadad (range 0-5), Delphi list (range 0-9), and numeric rating scale (NRS; range 1-10), based on User's Guides to the Medical Literature. RESULTS: A total of 196 articles were included in the analysis; most included hip (n = 81) or knee (n = 80) or both hip/knee arthroplasty (n = 19); 66 (34%) assessed pharmacological treatments, 117 (60%) nonpharmacological treatments, and 13 (7%) both. Mean (SEM) overall quality scores of arthroplasty @entity1 were low: Jadad score 2.36 (1.4), Delphi list 5.33 (1.6), and NRS score 4.30 (2.6). Multivariable analyses revealed that nonpharmacological intervention @entity1 had lower odds (odds ratio 0.28-0.39; p = 0.008-0.033) and those with no funding had lower odds (OR 0.28-0.50; p = 0.014-0.119) of being in the highest quartiles of the 3 overall quality scores. In contrast, multicenter @entity1 had 1.8-4.7 times higher odds of being in highest tertiles of quality scores (p = 0.017-0.185). CONCLUSION: @entity2 in reporting of hip/knee arthroplasty @entity1 offer an opportunity for improvement. Type of intervention, number of trial centers, and presence of funding were independently associated with overall trial quality. In future, multicenter @entity1 ( @entity1 ) and modeling protocols of single-center @entity1 similar in rigor to multicenter @entity1 may improve the quality of arthroplasty @entity1 .

title: Assessment of the methodologic quality of medical and surgical clinical trials in XXXX with arthroplasty.

answer: @entity0


abstract: The skin is an organ most often affected by @entity1 . Because of limited reactivity of the skin, different drugs may induce the same reactions on the skin, even if the same drug may induce different @entity1 . Many of these @entity1 do not include immunological mechanisms, most of them are non-immunological processes. @entity1 which involve an immune system, may appear different times after drug administration. The severity of reactions is not dependent on the time at which adverse drug reaction appeared, even if some life threatening @entity1 appear immediately after a drug administration. Four types of immunological reactions, (according to Cooms and Gell), may be involved in a drug adverse reaction. The first type of reaction (anaphylactic reaction) begins early after drug administration and different severities of the reactions could exist. The second type, known as cytotoxic @entity0 , begins after some minutes to a few hours after a drug administration. Third and fourth types of immunological reactions begin usually hours to days after drug administration. Some types of immunological reactions may begin days to weeks after drug administration. Sensitization to the drugs must be happen early, since re-exposition to the drug leads to the @entity1 . The way of sensitization sometimes determines which immune mechanism will be involved and which clinical reaction will appear. Tests in vivo and in vitro can be used in the diagnosis of @entity1 . All these tests are more or less limited to a false positive or false negative reaction and possibilities of serious reactions in tests. Provocations tests give the most satisfactory results but they may be dangerous and life threatening. We must carefully choose the skin tests and apply them according to the suspected pathomechanism of adverse drug reaction geneses and estimate the usefulness and the risks of the tests. Serious @entity1 (i.e. Sy @entity2 etc.) should not be tested. Some novel patents will have important implications in administration, diagnosis, and prevention of @entity1 .

title: Mechanisms of XXXX .

answer: @entity0


abstract: PURPOSE: The occurrence of @entity6 mutation is predictive of nonresponse and shorter survival in @entity0 treated by anti- @entity3 (anti- @entity3 ) antibody for metastatic @entity2 (mCRC), leading the European Medicine Agency to limit its use to @entity0 with wild-type @entity6 @entity1 . However, only half of these @entity0 will benefit from treatment, suggesting the need to identify additional biomarkers for cetuximab-based treatment efficacy. @entity0 AND METHODS: We retrospectively collected @entity1 from 173 @entity0 with mCRC. All but one @entity0 received a cetuximab-based regimen as second-line or greater therapy. @entity6 and @entity4 status were assessed by allelic discrimination. @entity3 amplification was assessed by chromogenic in situ hybridization and fluorescent in situ hybridization, and the expression of @entity5 was assessed by immunochemistry. RESULTS: In @entity0 with @entity6 wild-type @entity1 (n = 116), @entity4 mutations (n = 5) were weakly associated with lack of response (P = .063) but were strongly associated with shorter progression-free survival (P < .001) and shorter @entity7 ( @entity7 ; P < .001). A high @entity3 polysomy or an @entity3 amplification was found in 17.7% of the @entity0 and was associated with response (P = .015). @entity5 null expression was found in 19.9% of the @entity0 and was associated with shorter @entity7 (P = .013). In multivariate analysis, @entity4 mutation and @entity5 expression status were associated with @entity7 . CONCLUSION: @entity4 status, @entity3 amplification, and cytoplasmic expression of @entity5 were associated with outcome measures in @entity6 wild-type @entity0 treated with a cetuximab-based regimen. Subsequent studies in clinical trial cohorts will be required to confirm the clinical utility of these markers.

title: Analysis of @entity5 , @entity4 , and @entity3 status in determining benefit from cetuximab therapy in wild-type XXXX metastatic colon cancer.

answer: @entity6


abstract: PURPOSE: The occurrence of @entity6 mutation is predictive of nonresponse and shorter survival in @entity0 treated by anti- @entity3 (anti- @entity3 ) antibody for metastatic @entity2 (mCRC), leading the European Medicine Agency to limit its use to @entity0 with wild-type @entity6 @entity1 . However, only half of these @entity0 will benefit from treatment, suggesting the need to identify additional biomarkers for cetuximab-based treatment efficacy. @entity0 AND METHODS: We retrospectively collected @entity1 from 173 @entity0 with mCRC. All but one @entity0 received a cetuximab-based regimen as second-line or greater therapy. @entity6 and @entity4 status were assessed by allelic discrimination. @entity3 amplification was assessed by chromogenic in situ hybridization and fluorescent in situ hybridization, and the expression of @entity5 was assessed by immunochemistry. RESULTS: In @entity0 with @entity6 wild-type @entity1 (n = 116), @entity4 mutations (n = 5) were weakly associated with lack of response (P = .063) but were strongly associated with shorter progression-free survival (P < .001) and shorter @entity7 ( @entity7 ; P < .001). A high @entity3 polysomy or an @entity3 amplification was found in 17.7% of the @entity0 and was associated with response (P = .015). @entity5 null expression was found in 19.9% of the @entity0 and was associated with shorter @entity7 (P = .013). In multivariate analysis, @entity4 mutation and @entity5 expression status were associated with @entity7 . CONCLUSION: @entity4 status, @entity3 amplification, and cytoplasmic expression of @entity5 were associated with outcome measures in @entity6 wild-type @entity0 treated with a cetuximab-based regimen. Subsequent studies in clinical trial cohorts will be required to confirm the clinical utility of these markers.

title: Analysis of @entity5 , @entity4 , and XXXX status in determining benefit from cetuximab therapy in wild-type @entity6 metastatic colon cancer.

answer: @entity3


abstract: PURPOSE: The occurrence of @entity6 mutation is predictive of nonresponse and shorter survival in @entity0 treated by anti- @entity3 (anti- @entity3 ) antibody for metastatic @entity2 (mCRC), leading the European Medicine Agency to limit its use to @entity0 with wild-type @entity6 @entity1 . However, only half of these @entity0 will benefit from treatment, suggesting the need to identify additional biomarkers for cetuximab-based treatment efficacy. @entity0 AND METHODS: We retrospectively collected @entity1 from 173 @entity0 with mCRC. All but one @entity0 received a cetuximab-based regimen as second-line or greater therapy. @entity6 and @entity4 status were assessed by allelic discrimination. @entity3 amplification was assessed by chromogenic in situ hybridization and fluorescent in situ hybridization, and the expression of @entity5 was assessed by immunochemistry. RESULTS: In @entity0 with @entity6 wild-type @entity1 (n = 116), @entity4 mutations (n = 5) were weakly associated with lack of response (P = .063) but were strongly associated with shorter progression-free survival (P < .001) and shorter @entity7 ( @entity7 ; P < .001). A high @entity3 polysomy or an @entity3 amplification was found in 17.7% of the @entity0 and was associated with response (P = .015). @entity5 null expression was found in 19.9% of the @entity0 and was associated with shorter @entity7 (P = .013). In multivariate analysis, @entity4 mutation and @entity5 expression status were associated with @entity7 . CONCLUSION: @entity4 status, @entity3 amplification, and cytoplasmic expression of @entity5 were associated with outcome measures in @entity6 wild-type @entity0 treated with a cetuximab-based regimen. Subsequent studies in clinical trial cohorts will be required to confirm the clinical utility of these markers.

title: Analysis of @entity5 , XXXX , and @entity3 status in determining benefit from cetuximab therapy in wild-type @entity6 metastatic colon cancer.

answer: @entity4


abstract: PURPOSE: The occurrence of @entity6 mutation is predictive of nonresponse and shorter survival in @entity0 treated by anti- @entity3 (anti- @entity3 ) antibody for metastatic @entity2 (mCRC), leading the European Medicine Agency to limit its use to @entity0 with wild-type @entity6 @entity1 . However, only half of these @entity0 will benefit from treatment, suggesting the need to identify additional biomarkers for cetuximab-based treatment efficacy. @entity0 AND METHODS: We retrospectively collected @entity1 from 173 @entity0 with mCRC. All but one @entity0 received a cetuximab-based regimen as second-line or greater therapy. @entity6 and @entity4 status were assessed by allelic discrimination. @entity3 amplification was assessed by chromogenic in situ hybridization and fluorescent in situ hybridization, and the expression of @entity5 was assessed by immunochemistry. RESULTS: In @entity0 with @entity6 wild-type @entity1 (n = 116), @entity4 mutations (n = 5) were weakly associated with lack of response (P = .063) but were strongly associated with shorter progression-free survival (P < .001) and shorter @entity7 ( @entity7 ; P < .001). A high @entity3 polysomy or an @entity3 amplification was found in 17.7% of the @entity0 and was associated with response (P = .015). @entity5 null expression was found in 19.9% of the @entity0 and was associated with shorter @entity7 (P = .013). In multivariate analysis, @entity4 mutation and @entity5 expression status were associated with @entity7 . CONCLUSION: @entity4 status, @entity3 amplification, and cytoplasmic expression of @entity5 were associated with outcome measures in @entity6 wild-type @entity0 treated with a cetuximab-based regimen. Subsequent studies in clinical trial cohorts will be required to confirm the clinical utility of these markers.

title: Analysis of XXXX , @entity4 , and @entity3 status in determining benefit from cetuximab therapy in wild-type @entity6 metastatic colon cancer.

answer: @entity5


abstract: INTRODUCTION: To evaluate the incidence of @entity2 in @entity0 with @entity1 receiving @entity3 - @entity4 combination therapy ( @entity5 ) using data from the Japanese Gynecologic Oncology Group (JGOG) 3016 trial, and to examine the effect of severe @entity2 on survival during dose-dense @entity5 . METHODS: Retrospective analysis was conducted in @entity0 enrolled in the JGOG 3016 trial who underwent at least one cycle of the protocol therapy (n = 622). Hemoglobin values at enrollment and during each cycle of @entity5 were collected. One-to-one matching was performed between @entity0 with and @entity0 without grade 3/4 @entity2 during @entity5 ( @entity2 and nonanemia groups) to adjust the baseline characteristics of the @entity0 . The cumulative survival curve and median progression-free survival were estimated using the Kaplan-Meier method. RESULTS: Grades 2 to 4 @entity2 was observed in 19.8% of @entity0 before first-line @entity5 . The incidence of grade 3/4 @entity2 rapidly increased to 56.1% after the fourth cycle of dose-dense @entity5 . After matching, the median progression-free survival in the @entity2 (hemoglobin <8.0 g/dL) and nonanemia (hemoglobin >8.0 g/dL) groups was 777 and 1100 days, respectively (P = 0.3493) for @entity0 receiving dose-dense @entity5 . The median progression-free survival in @entity0 receiving conventional @entity5 was similar between the 2 groups. CONCLUSIONS: The difference in progression-free survival between @entity0 with @entity1 with and those without severe @entity2 during @entity5 was not statistically significant, but for @entity0 receiving dose-dense @entity5 , severe @entity2 seems to have prognostic relevance. Prospective trials are needed to investigate whether the optimal management of chemotherapy-induced @entity2 , including appropriate use of erythropoiesis-stimulating agents, would further improve the survival of @entity0 with @entity1 receiving dose-dense @entity5 .

title: Does severe @entity2 caused by dose-dense XXXX - @entity4 combination therapy have an effect on the survival of @entity0 with @entity1 ? Retrospective analysis of the Japanese gynecologic oncology group 3016 trial.

answer: @entity3


abstract: INTRODUCTION: To evaluate the incidence of @entity2 in @entity0 with @entity1 receiving @entity3 - @entity4 combination therapy ( @entity5 ) using data from the Japanese Gynecologic Oncology Group (JGOG) 3016 trial, and to examine the effect of severe @entity2 on survival during dose-dense @entity5 . METHODS: Retrospective analysis was conducted in @entity0 enrolled in the JGOG 3016 trial who underwent at least one cycle of the protocol therapy (n = 622). Hemoglobin values at enrollment and during each cycle of @entity5 were collected. One-to-one matching was performed between @entity0 with and @entity0 without grade 3/4 @entity2 during @entity5 ( @entity2 and nonanemia groups) to adjust the baseline characteristics of the @entity0 . The cumulative survival curve and median progression-free survival were estimated using the Kaplan-Meier method. RESULTS: Grades 2 to 4 @entity2 was observed in 19.8% of @entity0 before first-line @entity5 . The incidence of grade 3/4 @entity2 rapidly increased to 56.1% after the fourth cycle of dose-dense @entity5 . After matching, the median progression-free survival in the @entity2 (hemoglobin <8.0 g/dL) and nonanemia (hemoglobin >8.0 g/dL) groups was 777 and 1100 days, respectively (P = 0.3493) for @entity0 receiving dose-dense @entity5 . The median progression-free survival in @entity0 receiving conventional @entity5 was similar between the 2 groups. CONCLUSIONS: The difference in progression-free survival between @entity0 with @entity1 with and those without severe @entity2 during @entity5 was not statistically significant, but for @entity0 receiving dose-dense @entity5 , severe @entity2 seems to have prognostic relevance. Prospective trials are needed to investigate whether the optimal management of chemotherapy-induced @entity2 , including appropriate use of erythropoiesis-stimulating agents, would further improve the survival of @entity0 with @entity1 receiving dose-dense @entity5 .

title: Does severe @entity2 caused by dose-dense @entity3 - XXXX combination therapy have an effect on the survival of @entity0 with @entity1 ? Retrospective analysis of the Japanese gynecologic oncology group 3016 trial.

answer: @entity4


abstract: INTRODUCTION: To evaluate the incidence of @entity2 in @entity0 with @entity1 receiving @entity3 - @entity4 combination therapy ( @entity5 ) using data from the Japanese Gynecologic Oncology Group (JGOG) 3016 trial, and to examine the effect of severe @entity2 on survival during dose-dense @entity5 . METHODS: Retrospective analysis was conducted in @entity0 enrolled in the JGOG 3016 trial who underwent at least one cycle of the protocol therapy (n = 622). Hemoglobin values at enrollment and during each cycle of @entity5 were collected. One-to-one matching was performed between @entity0 with and @entity0 without grade 3/4 @entity2 during @entity5 ( @entity2 and nonanemia groups) to adjust the baseline characteristics of the @entity0 . The cumulative survival curve and median progression-free survival were estimated using the Kaplan-Meier method. RESULTS: Grades 2 to 4 @entity2 was observed in 19.8% of @entity0 before first-line @entity5 . The incidence of grade 3/4 @entity2 rapidly increased to 56.1% after the fourth cycle of dose-dense @entity5 . After matching, the median progression-free survival in the @entity2 (hemoglobin <8.0 g/dL) and nonanemia (hemoglobin >8.0 g/dL) groups was 777 and 1100 days, respectively (P = 0.3493) for @entity0 receiving dose-dense @entity5 . The median progression-free survival in @entity0 receiving conventional @entity5 was similar between the 2 groups. CONCLUSIONS: The difference in progression-free survival between @entity0 with @entity1 with and those without severe @entity2 during @entity5 was not statistically significant, but for @entity0 receiving dose-dense @entity5 , severe @entity2 seems to have prognostic relevance. Prospective trials are needed to investigate whether the optimal management of chemotherapy-induced @entity2 , including appropriate use of erythropoiesis-stimulating agents, would further improve the survival of @entity0 with @entity1 receiving dose-dense @entity5 .

title: Does severe XXXX caused by dose-dense @entity3 - @entity4 combination therapy have an effect on the survival of @entity0 with @entity1 ? Retrospective analysis of the Japanese gynecologic oncology group 3016 trial.

answer: @entity2


abstract: INTRODUCTION: To evaluate the incidence of @entity2 in @entity0 with @entity1 receiving @entity3 - @entity4 combination therapy ( @entity5 ) using data from the Japanese Gynecologic Oncology Group (JGOG) 3016 trial, and to examine the effect of severe @entity2 on survival during dose-dense @entity5 . METHODS: Retrospective analysis was conducted in @entity0 enrolled in the JGOG 3016 trial who underwent at least one cycle of the protocol therapy (n = 622). Hemoglobin values at enrollment and during each cycle of @entity5 were collected. One-to-one matching was performed between @entity0 with and @entity0 without grade 3/4 @entity2 during @entity5 ( @entity2 and nonanemia groups) to adjust the baseline characteristics of the @entity0 . The cumulative survival curve and median progression-free survival were estimated using the Kaplan-Meier method. RESULTS: Grades 2 to 4 @entity2 was observed in 19.8% of @entity0 before first-line @entity5 . The incidence of grade 3/4 @entity2 rapidly increased to 56.1% after the fourth cycle of dose-dense @entity5 . After matching, the median progression-free survival in the @entity2 (hemoglobin <8.0 g/dL) and nonanemia (hemoglobin >8.0 g/dL) groups was 777 and 1100 days, respectively (P = 0.3493) for @entity0 receiving dose-dense @entity5 . The median progression-free survival in @entity0 receiving conventional @entity5 was similar between the 2 groups. CONCLUSIONS: The difference in progression-free survival between @entity0 with @entity1 with and those without severe @entity2 during @entity5 was not statistically significant, but for @entity0 receiving dose-dense @entity5 , severe @entity2 seems to have prognostic relevance. Prospective trials are needed to investigate whether the optimal management of chemotherapy-induced @entity2 , including appropriate use of erythropoiesis-stimulating agents, would further improve the survival of @entity0 with @entity1 receiving dose-dense @entity5 .

title: Does severe @entity2 caused by dose-dense @entity3 - @entity4 combination therapy have an effect on the survival of @entity0 with XXXX ? Retrospective analysis of the Japanese gynecologic oncology group 3016 trial.

answer: @entity1


abstract: INTRODUCTION: To evaluate the incidence of @entity2 in @entity0 with @entity1 receiving @entity3 - @entity4 combination therapy ( @entity5 ) using data from the Japanese Gynecologic Oncology Group (JGOG) 3016 trial, and to examine the effect of severe @entity2 on survival during dose-dense @entity5 . METHODS: Retrospective analysis was conducted in @entity0 enrolled in the JGOG 3016 trial who underwent at least one cycle of the protocol therapy (n = 622). Hemoglobin values at enrollment and during each cycle of @entity5 were collected. One-to-one matching was performed between @entity0 with and @entity0 without grade 3/4 @entity2 during @entity5 ( @entity2 and nonanemia groups) to adjust the baseline characteristics of the @entity0 . The cumulative survival curve and median progression-free survival were estimated using the Kaplan-Meier method. RESULTS: Grades 2 to 4 @entity2 was observed in 19.8% of @entity0 before first-line @entity5 . The incidence of grade 3/4 @entity2 rapidly increased to 56.1% after the fourth cycle of dose-dense @entity5 . After matching, the median progression-free survival in the @entity2 (hemoglobin <8.0 g/dL) and nonanemia (hemoglobin >8.0 g/dL) groups was 777 and 1100 days, respectively (P = 0.3493) for @entity0 receiving dose-dense @entity5 . The median progression-free survival in @entity0 receiving conventional @entity5 was similar between the 2 groups. CONCLUSIONS: The difference in progression-free survival between @entity0 with @entity1 with and those without severe @entity2 during @entity5 was not statistically significant, but for @entity0 receiving dose-dense @entity5 , severe @entity2 seems to have prognostic relevance. Prospective trials are needed to investigate whether the optimal management of chemotherapy-induced @entity2 , including appropriate use of erythropoiesis-stimulating agents, would further improve the survival of @entity0 with @entity1 receiving dose-dense @entity5 .

title: Does severe @entity2 caused by dose-dense @entity3 - @entity4 combination therapy have an effect on the survival of XXXX with @entity1 ? Retrospective analysis of the Japanese gynecologic oncology group 3016 trial.

answer: @entity0


abstract: Persistent high-titre inhibitors after immune tolerance induction (ITI) increase the risks of @entity2 and @entity4 , resulting in high morbidity and mortality. Long-term prophylaxis with bypassing agents may avert these risks. This study was performed to assess the effectiveness and safety of early prophylaxis with @entity5 in preventing @entity2 and @entity1 after failed ITI. Seven paediatric @entity0 proceeded immediately after failed ITI to long-term @entity5 prophylaxis at 60-100 IU kg(-1) dosages and various dosing intervals depending upon @entity2 tendency. Bleeding episodes and joint status were assessed. Thrombin generation assays (TGA) were also used to gauge treatment response. @entity5 prophylaxis was commenced at a median age of 6.0 years (range, 1.5-11.8 years) and continued for a median duration of 6.9 years (range, 0.8-17.1 years). The mean annual incidence of @entity2 was 1.5 episodes per year with a 95% CI of 0.7-3.0 episodes per year. Muscle @entity2 incidence was 0.9 episodes per year (CI, 0.6-1.2 episodes per year). No @entity0 experienced major @entity1 during prophylaxis. Median Pettersson and orthopaedic joint scores at the last follow-up evaluation were 4 (range, 0-12) and 2 (range, 0-4) respectively. Endogenous thrombin potential (ETP) measured by TGA exceeded 80% of normal after @entity5 infusion in the majority of the @entity0 . Between regular prophylactic infusions, mean trough ETP equalled 2.6 fold of the inhibitor plasma control mean. @entity5 prophylaxis was well-tolerated without serious @entity3 or other complications. The only adverse event involved venous access. Therefore early long-term @entity5 prophylaxis is valuable in controlling @entity2 and preserving joint integrity in young @entity0 failing ITI.

title: Early long-term XXXX prophylaxis in haemophilia A @entity0 with inhibitor after failing immune tolerance induction: A prospective clinical case series.

answer: @entity5


abstract: Persistent high-titre inhibitors after immune tolerance induction (ITI) increase the risks of @entity2 and @entity4 , resulting in high morbidity and mortality. Long-term prophylaxis with bypassing agents may avert these risks. This study was performed to assess the effectiveness and safety of early prophylaxis with @entity5 in preventing @entity2 and @entity1 after failed ITI. Seven paediatric @entity0 proceeded immediately after failed ITI to long-term @entity5 prophylaxis at 60-100 IU kg(-1) dosages and various dosing intervals depending upon @entity2 tendency. Bleeding episodes and joint status were assessed. Thrombin generation assays (TGA) were also used to gauge treatment response. @entity5 prophylaxis was commenced at a median age of 6.0 years (range, 1.5-11.8 years) and continued for a median duration of 6.9 years (range, 0.8-17.1 years). The mean annual incidence of @entity2 was 1.5 episodes per year with a 95% CI of 0.7-3.0 episodes per year. Muscle @entity2 incidence was 0.9 episodes per year (CI, 0.6-1.2 episodes per year). No @entity0 experienced major @entity1 during prophylaxis. Median Pettersson and orthopaedic joint scores at the last follow-up evaluation were 4 (range, 0-12) and 2 (range, 0-4) respectively. Endogenous thrombin potential (ETP) measured by TGA exceeded 80% of normal after @entity5 infusion in the majority of the @entity0 . Between regular prophylactic infusions, mean trough ETP equalled 2.6 fold of the inhibitor plasma control mean. @entity5 prophylaxis was well-tolerated without serious @entity3 or other complications. The only adverse event involved venous access. Therefore early long-term @entity5 prophylaxis is valuable in controlling @entity2 and preserving joint integrity in young @entity0 failing ITI.

title: Early long-term @entity5 prophylaxis in haemophilia A XXXX with inhibitor after failing immune tolerance induction: A prospective clinical case series.

answer: @entity0


abstract: Following the success of the @entity1 ( @entity1 ), there has been considerable interest in technique modifications such as the transobturator approach for implant placement. We attempted to elucidate possible anatomical and clinical differences between the two methods in a retrospective cohort study. One hundred and fourteen @entity0 who had undergone @entity1 or Monarc implantation were assessed by or under the supervision of the senior author, with identical tensioning technique. They were followed up by an interview, uroflowmetry, and translabial 3D ultrasound. There were significant differences for @entity0 satisfaction (P=0.013), subjective overall cure/improvement (P=0.0018), and the symptom of poor stream (P=0.03), all favoring the Monarc group. On imaging Monarc tapes appeared more proximal at rest (P=0.006) and Valsalva (P=0.002) and remained further from the symphysis pubis on Valsalva (P=0.01). At 9 months follow-up, there was no significant difference as regards to cure rates for stress incontinence between the two suburethral slings. Monarc tapes are located more proximally and may be less obstructive, judging from a lower incidence of symptoms of @entity2 . @entity0 satisfaction and overall subjective cure/improvement were higher after Monarc. In summary, the Monarc is an effective @entity1 alternative, achieving cure of stress incontinence by similar means. It may be less obstructive, resulting in improved @entity0 satisfaction.

title: XXXX vs Monarc: a comparative study.

answer: @entity1


abstract: For @entity0 with diffuse pontine @entity2 , our institution offers local radiotherapy and supportive care only. The prognosis and do-not-resuscitate orders are discussed upfront with @entity0 ' parents. To investigate the effectiveness of this policy, we retrospectively reviewed records of @entity0 with diffuse pontine @entity2 treated at the institution over a 49-month period. This study included 19 @entity0 (16 @entity0 and 3 @entity0 ). The median age at diagnosis was 7 years. One @entity0 remained alive at the end of the study, 2 were lost to follow-up, and 16 were confirmed dead. The median survival was 8.2 months. Do-not-resuscitate discussion was documented for 14 @entity0 and successfully initiated for 11. None of those confirmed dead had been offered life support. Contrary to the common belief, our study showed that do not resuscitate should be addressed in Muslim @entity0 with high-risk @entity1 . We also found that diffuse pontine @entity2 warrants further study in developing countries.

title: Diffuse pontine XXXX in Jordan and impact of up-front prognosis disclosure with parents and families.

answer: @entity2


abstract: PURPOSE: To characterize the magnitude, time course, and specificity of @entity1 (PB)-mediated enzyme induction, and further, to develop an integrated pharmacokinetic (PK)-enzyme model describing the changes in the activities of CYP enzymes as well as in the PK of PB. METHODS: PB plasma concentrations and in vitro activities of several CYP enzymes were measured in @entity0 treated with PB between 0 and 14 days. A PB PK-enzyme induction model was developed using the program NONMEM: . RESULTS: PB treatment both induces and reduces the activity of CYP enzymes by stimulating the enzymes' formation or elimination rates. Certain CYP enzymes affected the PB PK through autoinduction. The half-life of the induction process was estimated to be 2 days for @entity3 , @entity6 , and @entity5 , and 3 days for @entity2 producing enzymes. The @entity4 activity was rapidly reduced by PB treatment. A lag time for the PB autoinduction was observed. This lag time is explained by the rate difference between induction and reduction in CYP activities. CONCLUSION: To our knowledge, this is the first example of an induction model that simultaneously describes plasma PK and in vitro data. It does so by integrating the bidirectional interaction between drug and enzymes in a mechanistic manner.

title: A mechanism-based integrated pharmacokinetic enzyme model describing the time course and magnitude of XXXX -mediated enzyme induction in the @entity0 .

answer: @entity1


abstract: PURPOSE: To characterize the magnitude, time course, and specificity of @entity1 (PB)-mediated enzyme induction, and further, to develop an integrated pharmacokinetic (PK)-enzyme model describing the changes in the activities of CYP enzymes as well as in the PK of PB. METHODS: PB plasma concentrations and in vitro activities of several CYP enzymes were measured in @entity0 treated with PB between 0 and 14 days. A PB PK-enzyme induction model was developed using the program NONMEM: . RESULTS: PB treatment both induces and reduces the activity of CYP enzymes by stimulating the enzymes' formation or elimination rates. Certain CYP enzymes affected the PB PK through autoinduction. The half-life of the induction process was estimated to be 2 days for @entity3 , @entity6 , and @entity5 , and 3 days for @entity2 producing enzymes. The @entity4 activity was rapidly reduced by PB treatment. A lag time for the PB autoinduction was observed. This lag time is explained by the rate difference between induction and reduction in CYP activities. CONCLUSION: To our knowledge, this is the first example of an induction model that simultaneously describes plasma PK and in vitro data. It does so by integrating the bidirectional interaction between drug and enzymes in a mechanistic manner.

title: A mechanism-based integrated pharmacokinetic enzyme model describing the time course and magnitude of @entity1 -mediated enzyme induction in the XXXX .

answer: @entity0


abstract: INTRODUCTION: @entity7 is a congenital @entity15 . This @entity11 involves the skeletal system, soft tissues, skin and vascular system. The most likely pathogenesis involves somatic mosaicism. Main manifestations included soft-tissue and @entity13 , partial @entity17 , @entity16 , exostoses, @entity4 and @entity5 . The most common @entity3 are hemimegencephaly and @entity2 . We present a case of @entity7 with @entity5 which are not described previously. CLINICAL CASE: Our @entity0 is a 61 year-old male who has @entity8 of the four limbs, @entity18 and @entity8 of chest and abdomen asymmetric with mild @entity14 . Prominent and abundant of the four extremities and trunk, also asymmetric. @entity1 in the skin of trunk and left limb. Cerebral MRI shows @entity12 and @entity6 . CONCLUSION: Clinical diagnostic criteria of @entity7 are documented in our @entity0 . He also has @entity10 which are not described previously in the literature. We consider that both findings are not a product of causality due to the high prevalence of @entity9 malformations in these @entity0 . We hypothesize that a single mutation, probably involving genes in relation with apoptotic control will be responsible of @entity7 and @entity5 in our @entity0 , due to a defect of angiogenesis.

title: [ @entity7 with XXXX ].

answer: @entity10